Literature DB >> 21596928

Regulation of human vascular protease-activated receptor-3 through mRNA stabilization and the transcription factor nuclear factor of activated T cells (NFAT).

Anke C Rosenkranz1, Bernhard H Rauch, Anke Doller, Wolfgang Eberhardt, Andreas Böhm, Ellen Bretschneider, Karsten Schrör.   

Abstract

Thrombin promotes vascular smooth muscle cell (SMC) proliferation and inflammation via protease-activated receptor (PAR)-1. A further thrombin receptor, PAR-3, acts as a PAR-1 cofactor in some cell-types. Unlike PAR-1, PAR-3 is dynamically regulated at the mRNA level in thrombin-stimulated SMC. This study investigated the mechanisms controlling PAR-3 expression. In human vascular SMC, PAR-3 siRNA attenuated thrombin-stimulated interleukin-6 expression and extracellular signal-regulated kinases 1/2 phosphorylation, indicating PAR-3 contributes to net thrombin responses in these cells. Thrombin slowed the decay of PAR-3 but not PAR-1 mRNA in the presence of actinomycin D and induced cytosolic shuttling and PAR-3 mRNA binding of the mRNA-stabilizing protein human antigen R (HuR). HuR siRNA prevented thrombin-induced PAR-3 expression. By contrast, forskolin inhibited HuR shuttling and destabilized PAR-3 mRNA, thus reducing PAR-3 mRNA and protein expression. Other cAMP-elevating agents, including the prostacyclin-mimetic iloprost, also down-regulated PAR-3, accompanied by decreased HuR/PAR-3 mRNA binding. Iloprost-induced suppression of PAR-3 was reversed with a myristoylated inhibitor of protein kinase A and mimicked by phorbol ester, an inducer of cyclooxygenase-2. In separate studies, iloprost attenuated PAR-3 promoter activity and prevented binding of nuclear factor of activated T cells (NFAT2) to the human PAR-3 promoter in a chromatin immunoprecipitation assay. Accordingly, PAR-3 expression was suppressed by the NFAT inhibitor cyclosporine A or NFAT2 siRNA. Thus human PAR-3, unlike PAR-1, is regulated post-transcriptionally via the mRNA-stabilizing factor HuR, whereas transcriptional control involves NFAT2. Through modulation of PAR-3 expression, prostacyclin and NFAT inhibitors may limit proliferative and inflammatory responses to thrombin after vessel injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596928     DOI: 10.1124/mol.111.072850

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

Review 1.  The role of nuclear factor of activated T cells in pulmonary arterial hypertension.

Authors:  Rui Chen; Jinchuan Yan; Peijing Liu; Zhongqun Wang; Cuiping Wang; Wei Zhong; Liangjie Xu
Journal:  Cell Cycle       Date:  2017-01-19       Impact factor: 4.534

Review 2.  Protease-activated receptors in hemostasis.

Authors:  Marvin T Nieman
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

3.  Prostacyclin influences the pressure reactivity in patients with severe traumatic brain injury treated with an ICP-targeted therapy.

Authors:  Lars-Owe D Koskinen; Anders Eklund; Nina Sundström; Magnus Olivecrona
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

4.  A Role for Protease Activated Receptor Type 3 (PAR3) in Nociception Demonstrated Through Development of a Novel Peptide Agonist.

Authors:  Juliet Mwirigi; Moeno Kume; Shayne N Hassler; Ayesha Ahmad; Pradipta R Ray; Changyu Jiang; Alexander Chamessian; Nakleh Mseeh; Breya P Ludwig; Benjamin D Rivera; Marvin T Nieman; Thomas Van de Ven; Ru-Rong Ji; Gregory Dussor; Scott Boitano; Josef Vagner; Theodore J Price
Journal:  J Pain       Date:  2021-01-09       Impact factor: 5.383

5.  Protease-activated receptor-2 signalling by tissue factor on dendritic cells suppresses antigen-specific CD4+ T-cell priming.

Authors:  Seema Shrivastava; Liang Ma; El-Li Tham; John H McVey; Daxin Chen; Anthony Dorling
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.